| Entry |
|
|---|
| Name |
Anagrelide hydrochloride hydrate (JAN);
Anagrelide hydrochloride monohydrate;
Agrylin (TN) |
|---|
| Product |
|
|---|
| Generic |
|
|---|
| Formula |
C10H7Cl2N3O. HCl. H2O
|
|---|
| Exact mass |
308.9839
|
|---|
| Mol weight |
310.5643
|
|---|
| Structure |
|
|---|
| Simcomp |
|
|---|
| Class |
Cardiovascular agent
DG01507 Phosphodiesterase III inhibitor
Metabolizing enzyme substrate
DG01891 CYP1A1 substrate
DG01892 CYP1A2 substrate
|
|---|
| Remark |
| Therapeutic category: | 4299 |
| Product (DG00727): | D10255<JP/US> |
|
|---|
| Efficacy |
Thrombocythemia treatment, Platelet aggregation inhibitor, Phosphodiesterase inhibitor |
|---|
| Target |
|
|---|
| Pathway |
|
|---|
| Metabolism |
Enzyme: CYP1A1 [HSA: 1543], CYP1A2 [HSA: 1544]
|
|---|
| Interaction |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XX Other antineoplastic agents
L01XX35 Anagrelide
D10255 Anagrelide hydrochloride hydrate (JAN) <JP/US>
USP drug classification [BR:br08302]
Blood Products and Modifiers
Blood Products and Modifiers, Other
Blood Products and Modifiers, Micellaneous
Anagrelide
D10255 Anagrelide hydrochloride hydrate (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4299 Others
D10255 Anagrelide hydrochloride hydrate (JAN)
Drug groups [BR:br08330]
Cardiovascular agent
DG01507 Phosphodiesterase III inhibitor
DG00727 Anagrelide
D10255 Anagrelide hydrochloride hydrate
Metabolizing enzyme substrate
DG01891 CYP1A1 substrate
DG00727 Anagrelide
D10255 Anagrelide hydrochloride hydrate
DG01892 CYP1A2 substrate
DG00727 Anagrelide
D10255 Anagrelide hydrochloride hydrate
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Phosphodiesterases
PDE3
D10255 Anagrelide hydrochloride hydrate (JAN) <JP/US>
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10255
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10255
Drug groups [BR:br08330]
Cardiovascular agent
DG01507 Phosphodiesterase III inhibitor
DG00727 Anagrelide
Metabolizing enzyme substrate
DG01891 CYP1A1 substrate
DG00727 Anagrelide
DG01892 CYP1A2 substrate
DG00727 Anagrelide
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
| KCF data |
ATOM 18
1 N1y N 20.7900 -16.7300
2 C2y C 20.7900 -18.1300
3 N2x N 19.6000 -18.8300
4 C8y C 18.3400 -18.1300
5 C8y C 18.3400 -16.7300
6 C1x C 19.5300 -16.0300
7 C8y C 17.1500 -16.0300
8 C8y C 15.8900 -16.7300
9 C8x C 15.8900 -18.1300
10 C8x C 17.1500 -18.8300
11 X Cl 17.1500 -14.6300
12 X Cl 14.7000 -16.0300
13 N1x N 22.1200 -18.5500
14 C5x C 22.8900 -17.4300
15 C1x C 22.1200 -16.3100
16 O5x O 24.2900 -17.4300
17 X Cl 26.8800 -15.7500
18 O0 O 27.3700 -18.8300
BOND 18
1 2 3 2
2 3 4 1
3 4 5 2
4 5 6 1
5 6 1 1
6 1 2 1
7 5 7 1
8 7 8 2
9 8 9 1
10 9 10 2
11 10 4 1
12 7 11 1
13 8 12 1
14 2 13 1
15 13 14 1
16 14 15 1
17 1 15 1
18 14 16 2
|
|---|
